Very excited to share our new preprint "#SARSCoV2 viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis" #IDTwitter
A huge team effort screening and synthesising the accumulating evidence. 1/6
2/6 Main findings:
- In the upper respiratory tract (URT), mean duration of RNA shedding was 17 days (95% CI, 15.5-18.6), max 83d
- Shedding duration increases with age & severity of illness
- There were limited studies reporting shedding duration in sputum (n=7) and stool (n=13)
3/6 - High SARS-CoV-2 viral loads in URT are detectable in the first week, and peak viral load occurs at day 0-5
- In contrast, peaks in SARS-1 and MERS occurred at days 10-14 and 7-10 of illness
- Pts with SARS-CoV-2 are likely to be most infectious day 0-5 (3/6)
4/6 - No study to date has cultured live virus beyond d9 in URT despite high viral loads (VL)
- The success of isolation correlated with VL quantified by PCR
- No successful viral culture when VL< 10^6 copies/ml, Ct values >24 or >34
- Only 2 studies cultured live virus in stool
5/6 - Viral loads at the start of infection appear to be comparable in asymptomatic and symptomatic patients but most studies demonstrate faster viral clearance in asymptomatic individuals
- There are limited data on the shedding of infectious virus in asymptomatic individuals
There is a lot of concern/confusion about vaccine effectiveness against the delta variant. How effective are the vaccines against Delta & how to interpret real-world observational data? So much misinformation is being circulated, so this thread brings key data together. 🧵(1/n)
Vaccine efficacy measures the relative reduction in infection/disease for the vaccinated vs unvaccinated arm. For instance, a vaccine that eliminates all risk would have an efficacy of 100%. Efficacy of 50% means you have a 50% reduced risk compared to an unvaxxed person. (2/n)
All studies assessing the performance of vaccines against Delta are based on real-world data (vaccine effectiveness), which are influenced by variant transmissibility, human behaviour, and immunity status of the population, therefore they require careful interpretation. (3/n)
There is a lot of confusion about the efficacy of AstraZeneca/ChAdOx1 vaccine against COVID19 due to B.1.351 / 501Y.V2 - summarising the results of phase 1b/2a double-blind randomized trial conducted in South Africa (based on @GovernmentZA press conference).🧵(1/6)
Adults aged 18-65 years without severe comorbidities and HIV were recruited. It was designed to show >60% efficacy against symptomatic disease, but because only 2000 participants were recruited with 42 total events, this analysis was not statistically powered. (2/6)
In total, 1749 participants were recruited, the population enrolled was young and generally healthy; the prevalence of hypertension, respiratory disease, and diabetes was low. Therefore, it was not designed to assess efficacy against severe disease. (3/6)
Concerns about outdoor transmission risk seem to be trending again. What is the risk of transmission outdoors and should we be more worried about outdoors with the new more-transmissible variant? 🧵(1/n)
The risk of transmission is complex and multi-dimensional. It depends on many factors: contact pattern (duration, proximity, activity), individual factors, environment (e.g. outdoor, indoor), socioeconomic factors, and mitigation measures in place. (2/n)(gov.uk/government/pub…\)
Transmission is facilitated by close proximity, prolonged contact, and frequency of contacts. So, the longer the time you spend with an infected person and the larger the gathering, the higher the risk is. (3/n) (academic.oup.com/cid/advance-ar…\)